Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 * Criteria specific to each tumor type: * For Clear cell renal cell carcinoma (ccRCC): advanced or recurrent disease. Must have failed at least 1 prior systemic therapy * For B-cell non-Hodgkin's lymphoma (B-NHL): Must have failed at least 1 prior systemic therapy * Measurable disease criteria by tumor type: * For ccRCC: At least 1 unidimensional measurable lesion * For B-NHL: At least 1 bidimensionally measurable lesion * Prior therapies for advanced/recurrent ccRCC or relapsed/refractory B-NHL or have become intolerant to a systemic therapy * Provide archived or fresh tumor tissue for CD70 status. Subjects must be CD70+ * Provision of fresh tissue (pre-treatment and on-treatment) for exploratory analysis is mandatory for at least 5 and a maximum of 10 B-NHL subjects Exclusion Criteria: * Prior therapy with an anti-CD70 antibody * History of severe hypersensitivity reactions to other monoclonal antibodies * Active or untreated central nervous system lymphoma * Active infection (viral, bacterial, or fungal) * Evidence of bleeding diathesis or coagulopathy * Active autoimmune disease requiring immunosuppressive therapy * Known current drug or alcohol abuse